ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

GUTS vs CTSO // ALTMAN Z-SCORE & DEBT/EQUITY

Fractyl Health Inc. (NASDAQ) VS. Cytosorbents Corporation (NASDAQ) • 15-METRIC TALLY: GUTS 0 — CTSO 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GUTS VS. CTSO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC GUTS CTSO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 71.50% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -39.80% — TIE /operating-margins <GO>
Net Profit Margin — -22.10% — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 CTSO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 17.2 46.6 -29.40 CTSO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $13.2M $13.9M -$712.6K CTSO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR GUTS REV CTSO REV GUTS GROSS % CTSO GROSS % GUTS FCF CTSO FCF
FY 2025 $0 $37.1M — 71.5% -$90.9M -$12.5M
FY 2024 $93.0K $35.6M 46.2% 69.9% -$67.3M -$14.7M
FY 2023 $0 $0 — — -$42.8M -$21.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GUTS // BETA —
CTSO // BETA —